In oligodendroglial neoplasms, losses of chromosomal material at 1p and 19q associate with chemosensitivity and prolonged survival. Thus, 1p/19q testing is increasingly proposed for use in brain tumor diagnosis and prognostic assessment. Fluorescent in situ hybridization (FISH) is a classic technique for investigation of 1p/19q status in paraffinembedded tissues. A major limitation of this method is truncation of tumor cell nuclei complicating assessment of hybridization results. In our study, we analyzed 1p and 19q status in a series of 79 oligodendroglial neoplasms (49 oligodendrogliomas, 30 oligoastrocytomas, WHO: 57 Grade II, 22 Grade III tumors) and controls (gliotic brain tissue: n ‫؍‬ 4, diffuse low-grade astrocytoma: n ‫؍‬ 4) using FISH on isolated whole tumor cell nuclei, prepared as cytospin preparations, thus bypassing the problem of nuclear truncation. For interpretation of FISH results, we used consensus criteria as defined by the SIOP-Europe Neuroblastoma Study Group for analysis of peripheral neuroblastic tumors. FISH yielded interpretable results in 98.7% for 1p and 92.1% for 19q. Chromosome 1p/19q alterations  comprised deletions (1p: 79.5%, 19q: 80%) and imbalances (1p: 11.5%, 19q: 12.9%) . 1p aberrations were more frequent in oligodendroglioma than in oligoastrocytoma (100% versus 75.9%, P ‫؍‬ .001). The frequency of 1p/19q alterations was not significantly different in WHO Grade II or Grade III tumors or in primary and recurrent tumors. We conclude that FISH on isolated cell nuclei, with application of the SIOP Europe Neuroblastoma consensus criteria, is a sensitive method for detection and interpretation of 1p and 19q aberrations in paraffin-embedded tissue specimens of oligodendroglial neoplasms.
with anaplastic oligodendrogliomas harboring a 1p/19q deletion were shown to have a more favorable prognosis and significantly better response to chemotherapy as compared with patients with intact 1p/19q status (1, 17, 19 -23) . In patients with diffuse low-grade gliomas, the 1p/19q status predicts prognosis (24) and the predictive value of 1p/19q status seems more reliable than histology (25) .
Therefore, it has been repeatedly suggested to amend conventional histological evaluation of anaplastic oligodendroglioma and diffuse low-grade gliomas with molecular analysis of chromosome arms 1p and 19q (1, 3, 9, 19 -22, 24 -26) . As a consequence, 1p/19q testing is increasingly proposed for use in the diagnostic setting. Various methods are used for 1p/19q deletion analysis, in particular PCR-based investigations (microsatellite analysis, real-time PCR), comparative genomic hybridization, and fluorescent in situ hybridization (FISH) techniques (12, 14, 24, (27) (28) (29) (30) . Consensus criteria for assessment and interpretation of analytical results in brain tumors are, however, lacking. In contrast, in peripheral neuroblastic tumors consensus criteria concerning methodology, evaluation of analytical results and data interpretation of diagnostic 1p testing are well established (31, 32) .
FISH is a classic technique for molecular cytogenetic testing on paraffin-embedded tissues (33) . FISH is not limited by age of material and does not require normal autologous or pooled normal reference tissue. Binding of probes can be controlled microscopically. However, one major limitation is nuclear truncation in tissue sections complicating evaluation and interpretation of hybridization results. To circumvent the problem of signal truncation, an improved FISH technique, that is, FISH on isolated whole tumor cell nuclei, has been developed for chromosome 1p analysis in germ cell tumors. Side-by-side comparison of both methods has proven that FISH on isolated tumor cell nuclei is superior as compared with conventional FISH on tissue sections (32) . FISH on isolated tumor cell nuclei has meanwhile replaced conventional FISH on tissue sections not only in germ cell tumors but also in other tumor types, most notably peripheral neuroblastic tumors (32, 34) . Studies on oligodendroglial neoplasms have continued to use conventional FISH on tissue sections. Therefore, we investigated applicability of FISH on isolated tumor cells on a large series of oligodendroglial neoplasms and assessed FISH results according to consensus criteria for 1p analysis in peripheral neuroblastic tumors, as defined by the International Society of Pediatric Oncology Europe (E-SIOP) Neuroblastoma Group (31) .
MATERIALS AND METHODS
A total of 89 paraffin-embedded archival tumor specimens diagnosed as low-and high-grade oligodendrogliomas and oligoastrocytomas were collected from the five major Austrian neuropathology/neurooncology units (Vienna, Graz, Innsbruck, Salzburg, and Linz). Age of the material ranged between 2 and 23 years. Control tissues comprised four cases of gliotic brain tissues (neurosurgically resected specimens of temporal lobe/Ammon's horn sclerosis) and 4 cases of diffuse low-grade astrocytoma. Histological slides, 4 m in thickness, were deparaffinized in xylol. Hematoxylin and eosin (HE) staining and immunohistochemistry for glial fibrillary acidic protein (GFAP, polyclonal antibody Z0334; DAKO, Glostrup, Denmark) and epithelial membrane antigen (EMA, monoclonal antibody E 29, DAKO) were performed according to standard protocols (35) . Immunolabeling was visualized with the ChemMate kit (DAKO) and diaminobenzidine as chromogene. The tumor specimens were reclassified according to WHO 2000 criteria (36) . Accordingly, we categorized those tumors as oligodendrogliomas which displayed uniform oligodendroglial morphology, and we categorized those tumors as oligoastrocytomas that contained distinct components with oligodendroglial and astrocytic differentiation ( Fig. 1 ). We used the anti-GFAP immunostaining pattern as support for the distinction of oligodendroglioma versus oligoastrocytoma. We considered a ring-like perinuclear "gliofibrillary" immunostaining pattern as a characteristic oligodendroglial feature, and we considered immunolabeling of a fibrillary tumor matrix as a characteristic feature of an astrocytic component. We used anti-EMA immunostaining for initial screening of the cases to exclude immunoreactive cell surface structures, a feature that would indicate clear cell ependymal neoplasms.
For FISH analysis, we marked representative tumor areas on HE stained sections. Corresponding areas were identified on the paraffin blocks, and core tissue biopsies of 1.5 mm in diameter were taken from each block using a Yamshidi needle. The same procedure was used for sampling of control tissues. We prepared isolated cell nuclei of tumor and control samples as described previously (32) . In detail, the paraffin-embedded tissue samples and 1-mm-diameter glass pellets were put into small bags of nylon gauze. The material was then deparaffinized with xylene for 1.5-3 hours, followed by an ethanol row with decreasing concentrations (100%, 90%, 70%, and 35% for 1 h, respectively). After transfer into distilled water, the deparaffinized tissue specimens were incubated with 0.1% protease (Sigma P8038, St. Louis, MO) in 0.1 N Tris-HCl at 37°C for 3-10 minutes and was agitated occasion-ally. Afterwards, the digestion was stopped on ice. For checking of digestion, 10 L of 4'-6-diamidino-2-phenylindole-2HCl (DAPI; 0.002 L/mL PBS) and 10 L of cell suspension were put on a slide, cov-ered by coverslip and examined under the fluorescence microscope. Cytospins on glass slides were prepared by centrifugation of 50 -100 L cell suspensions (8 min, 500 rpm) with the help of a SHANDON-Cytospin 2 cytocentrifuge (Pittsburgh, PA). The cytospin preparations were air-dried for 2-24 hours and fixed with 4% buffered formaldehyde for 10 minutes. The samples were immediately processed for FISH or stored before FISH in sealed boxes at Ϫ20°C or Ϫ80°C. 1p analysis was performed with the paracentromeric probe D1Z1 (1q12) (37) and subtelomeric probe D1Z2 (1p36.3; both Q-BIOgene, Heidelberg, Germany) in a double-color FISH approach as described previously. For 19q analysis, probes 19pter and 19q13.3 were used (both Vysis, Bergish-Gladbach, Germany). For visualization, the probes were either directly fluorescence labeled or biotin/digoxigeninlabeled probes were detected with fluorescencelabeled antibodies.
Assessment and interpretation of FISH results were performed according to guidelines defined by the International Society of Pediatric Oncology (E-SIOP Neuroblastoma Study Group) for studies of peripheral neuroblastic tumors (31) . In each case, hybridization signals of Ն200 tumor cell nuclei were assessed. The ratios between the numbers of paracentromeric and subtelomeric regions of chromosomes 1p and 19q were calculated.
Deletion: ratio of paracentromeric and subtelomeric signals ϭ 2/1, partially in conjunction with 4/2, 3/1, 4/1 ratios. This hybridization pattern indicates the presence of an LOH.
Imbalance: disproportion of the ratio of paracentromeric and subtelomeric signals, number of subtelomeric signals Ͼ1 (ϭ3/2, 4/3, 4/2, 5/3, etc.). Such a result can indicate but does not prove an LOH. Clarification of this specific question requires complementary techniques, such as PCR or Southern blot analysis.
No deletion, no imbalance-normal result: equal ratio of paracentromeric and subtelomeric signals ϭ 2/2, 4/4.
Unclear result: result is not interpretable because of material (too little tissue, calcifications, etc.) or technical reasons (enzymatic overdigestion).
Statistical testing was performed using 2 test and statistic as appropriate. Two-tailed P values Յ.05 were considered as statistically significant.
RESULTS
On histological review, we classified 49 specimens as pure oligodendrogliomas and 30 specimens as oligoastrocytomas. Ten tumors were excluded from further analysis because histology revealed features of clear cell ependymoma in 3 cases, subependymoma in one case, astrocytoma in two cases, primitive neuroectodermal tumor (PNET) in one case, glioblastoma with focal oligodendroglial features in one case, and unclassifiable clear cell gliomas in two cases. The cohort of oligodendroglial neoplasms included 59 primary and 20 recurrent tumors. Fifty-seven specimens fulfilled criteria of Grade II, and 22 cases, Grade III, according to current WHO grading criteria.
We performed 1p analysis in 79/79 tumor cases and 19q analysis in 76/79 tumor cases. In addition, we performed 1p/19q analysis in 8/8 controls. FISH showed intact 1p and 19q status (2:2 ratio) in 4/4 gliotic brain tissue samples and in 4/4 diffuse astrocytomas, used as controls. Results in the cohort of oligodendroglial neoplasms are summarized in Table 1 . FISH yielded interpretable results in 98.7% (78/79) for 1p and in 92.1% (70/76) for 19q. In the remaining cases, results were unclear, because of material (too little tissue, too low tumor cell content in tissue, calcification of the tissue) or methodology (enzymatic overdigestion). In the cohorts with interpretable results (discounting the cases with unclear results), 79.5% (62/78) had 1p deletion and 11.5% (9/78) had 1p imbalance, 80.0% (56/70) had 19q deletion, and 12.9% (9/70) had 19q imbalance. In the total group (including cases with unclear results), 56/76 (73,7%) had 19q deletion, and 9/76 (11,8%) had 19q imbalance. Aberrations in 1p were always present in oligodendrogliomas but not in all oligoastrocytomas (100% versus 75.9%, exact 2 test: P ϭ .001). Figure 2 shows representative FISH results.
There was a tight positive association of 1p and 19q alterations ( 
DISCUSSION
DNA gains and losses are common alterations in a host of tumors, and some of these DNA alterations correlate with clinical outcome and therapy response (38) . In case of primary brain tumors, DNA losses on chromosomes 1p and 19q associate with the oligodendroglial phenotype. Clinicopathological correlation analysis has disclosed that 1p and 19q aberrations in oligodendroglial neoplasms are predictive for patient survival and chemoresponsiveness (1, 3, 7, 16, 20, 22-24, 29, 39) . Therefore, determination of the 1p/19q status is increasingly proposed to be integrated in the diagnostic setting, amending histology (26) . Among various techniques, PCR-microsatellite analysis is commonly used for 1p and 19q investigations (28 -30) . This technique is relatively cheap and fast. However, a major limitation is the need for paired blood samples. In addition, for this kind of studies, the tumor cell content must not be Ͻ60%. Leukocyte preparation in parallel to brain tumor processing and freezing of tumor samples for molecular analysis has not yet become standard in many neuropathology laboratories or is not possible because of lack of dedicated personnel and laboratory space. For 1p/19q testing, such laboratories have to resort to methods that work on paraffin-embedded brain tumor samples and which do not require paired blood samples. Fulfilling this criterion, FISH is a good method for 1p/19q testing on paraffin- 19q deletion  55  0  1  0  56  19q imbalance  2  6  1  0  9  19q normal  2  0  3  0  5  19q unclear  3  3  0  0  6  19q not done  0  0  2  1  3  62  9  7  1 embedded tissue samples (22, 24, 30) . A further advantage of the FISH technique as compared with PCR is the possibility of investigating tumor tissue at the cellular level. Thus, correlation with morphology and immunocytology, if needed, can be performed. Tumor cell content can be Ͻ60% (the limit for LOH studies), and paired blood samples are not needed allowing the use of archival material. Conventional FISH analysis is performed on histological sections and, therefore, fraught with the problem of nuclear truncation due to cutting of cell nuclei. Assessment of FISH results on sections is a time consuming procedure requiring statistic evaluation of several hundred tumor cell nuclei in each case. For taking nuclear truncation into account, a numerical cutoff of signal ratios has to be defined. In cases with results close to the cutoff value, 1p and 19q may not be unequivocally classifiable as normal or abnormal. This problem is in particular grave in tumors composed of large tumor cells (e.g., peripheral neuroblastic tumors) with an inherently higher rate of nuclear truncation on histological sections (32, 33, 40, 41) . FISH on isolated cell nuclei circumvents the problem of nuclear truncation. In contrast to FISH on histological sections, tumor cell nuclei are isolated mechanically and enzymatically from paraffin-embedded tissue specimens. FISH is then performed on cytospin preparations of the tumor cell nuclei. In case of peripheral neuroblastic tumors, FISH on isolated cell nuclei has proven superior and has replaced conventional FISH on histological sections (31, 32, 34) . To our knowledge, this method has been used so far only in a small series of brain tumors (42) . Our study on a large series of oligodendroglial neoplasms shows that FISH on isolated cell nuclei of oligodendroglial neoplasms is a sensitive method for 1p and 19q analysis. Using E-SIOP criteria, the yield of interpretable results is 98.7% for 1p and 92.1% for 19q.
The majority of our cases with abnormal 1p/19q displayed a 2:1 ratio of paracentromeric and subtelomeric FISH signals, definitely indicating an LOH status. However, a portion of tumor specimens showed other abnormal ratios with subtelomeric signals Ͼ1, for instance, 3:2, 4:3, 5:3 ratios (11.5% for 1p and 12.9% for 19q). Such ratios can imply but do not prove an LOH. Therefore, the E-SIOP Neuroblastoma Study Group has designated these ratios as FISH imbalance (31) . Previous FISH studies analyzing 1p/19q status in brain tumors have not discriminated between deletion and imbalance status. It will be important to clarify in future prospective studies the 1p and 19q status in oligodendroglial neoplasms with FISH imbalance using FISH and PCR techniques in parallel. Only if FISH imbalance in oligodendroglial neoplasms consistently represents an LOH status, FISH can be used as sole technique for 1p/19q analysis. If FISH imbalance includes oligodendroglial neoplasms with and without a deletion status, PCR analysis will be mandatory as complementary technique, as is the case in peripheral neuroblastic tumors. Clarification of this issue is important for translation of FISH-based 1p/19q testing on brain tumors into common clinical use.
The majority of our patients received adjuvant radio-and chemotherapy after first operation. These treatments have DNA damaging effects. A possible effect could be the increase of polyploidization of tumor cells and, as a consequence, an increase of the rate of FISH imbalance status (e.g., 4/2 instead of 2/1, or 6/2 instead of 3/1). Comparing the frequencies of FISH imbalance in primary and recurrent tumors, we did not detect a significant difference. Thus, tumor recurrency and adjuvant treatment seem not to diminish the diagnostic yield of FISH.
In our cohort of oligodendroglial neoplasms, we found a tight positive association of 1p and 19q aberrations. Only 5.7% (4/70) showed either isolated 1p or 19q alteration and 96.9% (63/65) of the cases with 1p alteration had in addition 19q alteration. 1p and 19q losses were also tightly associated in other, previously published series of oligodendroglial neoplasms (12, 16, 18, 20, 24, 27, 30, 36, 43, 44) . On the basis of the 1p/19q status, stratification of adjuvant therapy of anaplastic oligodendroglioma has been proposed (20, 26) . According to this proposal, initial chemotherapy but without radiotherapy should be reserved for patients with combined 1p/19q losses, whereas patients with isolated 1p loss should be treated with combined chemotherapy and radiotherapy. However, oligodendrogliomas with isolated 1p loss are rather rare. As survival analysis has been performed so far only in relative small patient cohorts, it has not been proven unequivocally whether there is indeed a significant difference of prognosis and/or response to adjuvant therapy in patients with isolated 1p loss as compared with patients with combined 1p/19q loss. This issue needs to be clarified before stratification of adjuvant treatment on basis of 1p/19q status can be translated into common clinical use. This will require investigations of large prospective patient cohorts using carefully validated laboratory techniques for 1p/19q analysis.
